Clinical observations on the potential of pre-hospital antiplatelet therapy in preventing ARDS have been inconsistent. To further the correlation between antiplatelet therapy and ARDS, we conducted a meta-analysis to evaluate the effects of pre-hospital antiplatelet therapy on subjects with ARDS.
METHODS:
A literature search in major data banks was performed. We included prospective and retrospective cohorts, case-control trials, and randomized controlled trials that compared the ARDS incidence in subjects with or without pre-hospital antiplatelet agents.
RESULTS:
Meta-analysis of 7 studies (a total of 30,291 subjects) showed significantly lower odds of ARDS in the pre-hospital antiplatelet therapy group compared with subjects with no pre-hospital antiplatelet therapy (odds ratio 0.68, 95% CI 0.56–0.83; P < .001). However, ARDS mortalities in the hospital and ICUs were not affected.
CONCLUSIONS:
These findings indicated that pre-hospital antiplatelet therapy was associated with a reduced rate of ARDS but had no effect on the mortality in the subjects at high risk.
BellaniG, LaffeyJG, PhamT, FanE, BrochardL, EstebanA, et al. Epidemiology, patterns of care, and mortality for subjects with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA, 2016; 315(8):788-800.
2.
ParharKKS, ZjadewiczK, SooA, SuttonA, ZjadewiczM, DoigL, et al. Epidemiology, mechanical power, and 3-year outcomes in acute respiratory distress syndrome patients using standardized screening: an observational cohort study. Ann Am Thorac Soc, 2019; 16(10):1263-1272.
3.
VillarJ, BlancoJ, KacmarekRM. Current incidence and outcome of the acute respiratory distress syndrome. Curr Opin Crit Care, 2016; 22(1):1-6.
4.
MaK, PatelK, NaddourM, ViraniA, AdurtyR, AlhajHusainA, CheemaT. Acute respiratory distress syndrome novel therapies. Crit Care Nurs Q, 2019; 42(4):411-416.
5.
CuttsS, TalboysR, PaspulaC, PrempehEM, FanousR, AilD. Adult respiratory distress syndrome. Ann R Coll Surg Engl, 2017; 99(1):12-16.
6.
EworukeE, MajorJM, Gilbert McClainL. National incidence rates for acute respiratory distress syndrome (ARDS) and ARDS cause-specific factors in the United States (2006–2014). J Crit Care, 2018; 47:192-197.
7.
BeloncleF, MercatA. Approaches and techniques to avoid development or progression of acute respiratory distress syndrome. Curr Opin Crit Care, 2018; 24(1):10-15.
8.
FlannaganKS, SjaardaLA, HillMJ, ConnellMT, ZoltonJR, PerkinsNJ, et al. Pilot randomized trial of short-term changes in inflammation and lipid levels during and after aspirin and pravastatin therapy. Reprod Health, 2019; 16(1):132.
9.
WangXL, DengHF, LiT, MiaoSY, XiaoZH, LiuMD, et al. Clopidogrel reduces lipopolysaccharide-induced inflammation and neutrophil-platelet aggregates in an experimental endotoxemic model. J Biochem Mol Toxicol, 2019; 33(4):e22279.
HamidU, KrasnodembskayaA, FitzgeraldM, ShyamsundarM, KissenpfennigA, ScottC, et al. Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS. Thorax, 2017; 72(11):971-980.
12.
Morales-OrtízJ, DealV, ReyesF, Maldonado-MartínezG, LedesmaN, StabackF, et al. Platelet-derived TLT-1 is a prognostic indicator in ALI/ARDS and prevents tissue damage in the lungs in a mouse model. Blood, 2018; 132(23):2495-2505.
13.
NieriD, NeriT, PetriniS, VagagginiB, PaggiaroP, CeliA. Cell-derived microparticles and the lung. Eur Respir Rev, 2016; 25(141):266-277.
14.
ZucolotoAZ, JenneCN. Platelet-neutrophil interplay: insights into neutrophil extracellular trap (NET)-driven coagulation in infection. Front Cardiovasc Med, 2019; 6:85.
15.
WangY, OuyangY, LiuB, MaX, DingR. Platelet activation and antiplatelet therapy in sepsis: a narrative review. Thromb Res, 2018; 166:28-36.
16.
KorDJ, CarterRE, ParkPK, FesticE, Banner-GoodspeedVM, HindsR, et al. Effect of aspirin on development of ARDS in at-risk subjects presenting to the emergency department the LIPS-a randomized clinical trial. JAMA, 2016; 315(22):2406-2414.
17.
AbdulnourRE, GundersonT, BarkasI, TimmonsJY, BarnigC, GongM, et al. Early intravascular events are associated with development of acute respiratory distress syndrome: a substudy of the LIPS-A clinical trial. Am J Respir Crit Care Med, 2018; 197(12):1575-1585.
18.
KorDJ, ErlichJ, GongMN, MalinchocM, CarterRE, GajicO, et al. U.S. Critical Illness and Injury Trials Group; Lung Injury Prevention Study Investigators. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk subjects. Crit Care Med, 2011; 39(11):2393-2400.
19.
ChenW, JanzDR, BastaracheJA, MayAK, O'NealHRJr, BernardGR, WareLB. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill subjects: a propensity-adjusted analysis. Crit Care Med, 2015; 43(4):801-807.
20.
MazzeffiM, KassaW, GammieJ, TanakaK, RomanP, ZhanM, et al. Preoperative aspirin use and lung injury after aortic valve replacement surgery: a retrospective cohort study. Anesth Analg, 2015; 121(2):271-277.
21.
ARDS Definition Task Force, RanieriVM, RubenfeldGD, ThompsonBT, FergusonND, CaldwellE, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA, 2012; 307(23):2526-2533.
22.
ErlichJM, TalmorDS, Cartin-CebaR, GajicO, KorDJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest, 2011; 139(2):289-295.
23.
Valerio-RojasJC, JafferIJ, KorDJ, GajicO, Cartin-CebaR. Outcomes of severe sepsis and septic shock subjects on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract, 2013; 2013:782573.
24.
TuinmanPR, VlaarAP, BinnenkadeJM, JuffermansNP. The effect of aspirin in transfusion-related acute lung injury in critically ill subjects. Anaesthesia, 2012; 67(6):594-599.
25.
GrossAK, DunnSP, FeolaDJ, MartinCA, CharnigoR, LiZ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis, 2013; 35(2):147-154.
26.
BernardGR, ArtigasA, BrighamKL, CarletJ, FalkeK, HudsonL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med, 1994; 149(3 Pt 1):818-824.
27.
BoyleAJ, Di GangiS, HamidUI, MottramLJ, McNameeL, WhiteG, et al. Aspirin therapy in subjects with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care, 2015; 19:109.
28.
PankaBA, de GroothHJ, Spoelstra-de ManAM, LooneyMR, TuinmanPR. Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta-analysis of clinical studies. Shock, 2017; 47(1):13-21.
29.
HuX, ShenH, WangY, ZhangL, ZhaoM. Aspirin-triggered resolvin D1 alleviates paraquat-induced acute lung injury in mice. Life Sci, 2019; 218:38-46.
30.
ZhuJ, GaoB. Simvastatin combined with aspirin increases the survival time of heart allograft by activating CD4(+)CD25(+) Treg cells and enhancing vascular endothelial cell protection. Cardiovasc Pathol, 2015; 24(3):173-178.
31.
JózsefL, ZoukiC, PetasisNA, SerhanCN, FilepJG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A, 2002; 99(20):13266-13271.
32.
MorrisT, StablesM, HobbsA, de SouzaP, Colville-NashP, WarnerT, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol, 2009; 183(3):2089-2096.
33.
OuyangY, WangY, LiuB, MaX, DingR. Effects of antiplatelet therapy on the mortality rate of patients with sepsis: a meta-analysis. J Crit Care, 2019; 50:162-168.
